Epionce Funding: How Much Did They Raise & Key Investors

How Much Did Epionce Raise?
Funding & Key Investors

Episciences, Inc., the parent organization behind the professional-grade skincare line Epionce, has successfully secured a major strategic investment. This latest capital injection, totaling $1M, underscores the company's robust market position within the competitive cosmeceutical sector. With a cumulative financial backing of $1M, the firm is well-positioned to accelerate its research-driven initiatives and expand its footprint in the dermatological wellness market.

The infusion of this capital serves as a pivotal milestone for the Boise-based entity, which has spent over two decades refining its proprietary botanical formulations. By prioritizing clinical validation and professional distribution channels, Epionce has established itself as a high-authority player in the skin health industry, effectively bridging the gap between traditional dermatology and consumer-facing wellness solutions.

What is Epionce?

Epionce

Manufacturing

Cosmetics, Beauty Supply & Personal Care Products

Business Services

Founded in 2002, Episciences, Inc. operates at the intersection of advanced biotechnology and dermatological science. The company specializes in the development of non-prescription, high-efficacy products designed to address visible skin aging and chronic skin conditions. Unlike conventional beauty brands, Epionce leverages a unique sub-layer delivery system and patent-pending ingredient complexes to optimize the skin's natural reparative mechanisms. Its market strategy is anchored in clinical rigor, supported by over 12 independent, double-blind studies that validate its therapeutic claims. By distributing exclusively through dermatologists, plastic surgeons, and licensed skincare professionals, the company maintains a premium brand identity that emphasizes medical-grade results and long-term skin health.

How much funding has Epionce raised?

Epionce has raised a total of $1M across 1 funding round:

2020

Debt

$1M

Debt (2020): $1M with participation from PPP

Key Investors in Epionce

PPP

Public-Private Partnership

What's next for Epionce?

With the recent influx of capital, Episciences, Inc. is poised to scale its operational capabilities and deepen its investment in R&D. The strategic roadmap likely involves expanding its patent-pending product portfolio and strengthening its presence within the global professional skincare market. As the demand for evidence-based, non-prescription dermatological solutions continues to rise, Epionce is strategically positioned to capture additional market share. Future growth will likely focus on enhancing its proprietary delivery systems and potentially exploring new therapeutic applications for its botanical formulations, ensuring the company remains at the forefront of the skin wellness paradigm.

See full Epionce company page

See More Financial Insights